REFERENCES
1. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Prim 2018;4:1-18.
2. von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia Sarcopenia Muscle 2016;7:507-9.
3. Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, et al. Why cachexia kills: Examining the causality of poor outcomes in wasting conditions. J Cachexia Sarcopenia Muscle 2013;4:89-94.
4. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, et al. Cachexia:a new definition. Clin Nutr 2008;27:793-9.
5. Pin F, Couch ME, Bonetto A. Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr Opin Support Palliat Care 2018;12:420-6.
6. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014;14:754-62.
7. Penna F, Ballarò R, Martinez-cristobal P, Sebastian D, Busquets S, et al. Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J Mol Biol 2019:2674-86.
8. Penna F, Costamagna D, Pin F, Camperi A, Fanzani A, et al. Autophagic degradation contributes to muscle wasting in cancer cachexia. Am J Pathol 2013;182:1367-78.
9. Penna F, Bonetto A, Aversa Z, Minero VG, Rossi Fanelli F, et al. Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J Cachexia Sarcopenia Muscle 2015;7:345-54.
10. Penna F, Ballarò R, Beltrá M, De Lucia S, Costelli P. Modulating metabolism to improve cancer-induced muscle wasting. Oxid Med Cell Longev 2018;2018:7153610.
11. von Meyenfeldt M. Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs 2005;9:35-8.
12. Collins P, Bing C, McCulloch P, Williams G. Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Br J Cancer 2002;86:372-5.
13. Julienne CM, Dumas JF, Goupille C, Pinault M, Berri C, et al. Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency. J Cachexia Sarcopenia Muscle 2012;3:265-75.
14. Busquets S, Almendro V, Barreiro E, Figueras M, Argilés JM, et al. Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake: Involvement of ROS in a model of mouse cancer cachexia. FEBS Lett 2005;579:717-22.
15. Argilés JM, López-Soriano FJ, Busquets S. Muscle wasting in cancer: the role of mitochondria. Curr Opin Clin Nutr Metab Care 2015;18:221-5.
16. Brown JL, Rosa-Caldwell ME, Lee DE, Blackwell TA, Brown LA, et al. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour bearing mice. J Cachexia Sarcopenia Muscle 2017;8:926-38.
17. Shum AMY, Poljak A, Bentley NL, Turner N, Tan TC, et al. Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: alterations in sarcomeric and mitochondrial protein expression. Oncotarget 2018;9:22001-22.
18. Marzetti E, Lorenzi M, Landi F, Picca A, Rosa F, et al. Altered mitochondrial quality control signaling in muscle of old gastric cancer patients with cachexia. Exp Gerontol 2017;87:92-9.
19. Aversa Z, Pin F, Lucia S, Penna F, Verzaro R, et al. Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci Rep 2016;6:30340.
20. Barreto R, Waning DL, Gao H, Liu Y, Zimmers TA, et al. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget 2016;7:43442-60.
21. Ballaro R, Beltra M, De Lucia S, Pin F, Ranjbar K, et al. Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J 2019;33:5482-94.
22. Barreto R, Mandili G, Witzmann FA, Novelli F, Zimmers TA, et al. Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front Physiol 2016;7:1-13.
23. Pin F, Bonetto A, Oconnell T. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J Cachexia Sarcopenia Muscle 2019;10:140-54.
24. Viña J, Sanchis-Gomar F, Martinez-Bello V, Gomez-Cabrera MC. Exercise acts as a drug; The pharmacological benefits of exercise. Br J Pharmacol 2012;167:1-12.
25. Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab 2013;17:162-84.
26. Hardee JP, Counts BR, Carson JA. Understanding the role of exercise in cancer cachexia therapy. Am J Lifestyle Med 2017;13:46-60.
27. Coletti D. Exercise against tumor- and chemotherapy-induced muscle wasting. Biol Eng Med 2018;3:1-5.
28. Padilha CS, Borges FH, Costa Mendes da Silva LE, Frajacomo FTT, Jordao AA, et al. Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats. Appl Physiol Nutr Metab 2017;42:916-23.
29. Donatto FF, Neves RX, Rosa FO, Camargo RG, Ribeiro H, et al. Resistance exercise modulates lipid plasma profile and cytokine content in the adipose tissue of tumour-bearing rats. Cytokine 2013;61:426-32.
30. Khamoui AV, Park BS, Kim DH, Yeh MC, Oh SL, et al. Aerobic and resistance training dependent skeletal muscle plasticity in the colon-26 murine model of cancer cachexia. Metabolism 2016;65:685-98.
31. Puppa MJ, White JP, Velázquez KT, Baltgalvis KA, Sato S, et al. The effect of exercise on IL-6-induced cachexia in the ApcMin/+ mouse. J Cachexia Sarcopenia Muscle 2012;3:117-37.
32. White JP, Puppa MJ, Sato S, Gao S, Price RL, et al. IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse. Skelet Muscle 2012;2:14.
33. Pigna E, Berardi E, Aulino P, Rizzuto E, Zampieri S, et al. Aerobic Exercise and Pharmacological Treatments Counteract Cachexia by Modulating Autophagy in Colon Cancer. Sci Rep 2016;6:26691.
34. Ballarò R, Penna F, Pin F, Gómez-Cabrera MC, Viña J, et al. Moderate Exercise Improves Experimental Cancer Cachexia by Modulating the Redox Homeostasis. Cancers (Basel) 2019;11:E285.
35. Pin F, Busquets S, Toledo M, Camperi A, Lopez-Soriano FJ, et al. Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget 2015;6:43202-15.
36. Ranjbar K, Ballaro R, Bover Q, Pin F, Beltra M, et al. Combined exercise training positively affects muscle wasting in tumor-bearing mice. Med Sci Sports Exerc 2019;51:1387-95.
37. Cave J, Paschalis A, Huang CY, West M, Copson E, et al. A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Support Care Cancer 2018;26:3337-51.
38. Mijwel S, Cardinale DA, Norrbom J, Chapman M, Ivarsson N, et al. Exercise training during chemotherapy preserves skeletal muscle fiber area, capillarization, and mitochondrial content in patients with breast cancer. FASEB J 2018;32:5495-505.
39. Wiskemann J, Clauss D, Tjaden C, Hackert T, Schneider L, et al. Progressive resistance training to impact physical fitness and body weight in pancreatic cancer patients: a randomized controlled trial. Pancreas 2019;48:257-66.
40. Grote M, Maihöfer C, Weigl M, Davies-Knorr P, Belka C. Progressive resistance training in cachectic head and neck cancer patients undergoing radiotherapy: a randomized controlled pilot feasibility trial. Radiat Oncol 2018;13:1-10.
41. Wasley D, Gale N, Roberts S, Backx K, Nelson A, et al. Patients with established cancer cachexia lack the motivation and self-efficacy to undertake regular structured exercise. Psychooncology 2018;27:458-64.
42. Antoun S, Raynard B. Muscle protein anabolism in advanced cancer patients:response to protein and amino acids support, and to physical activity. Ann Oncol 2018;29:ii10-7.
43. Argilés JM, Busquets S, López-Soriano FJ, Costelli P, Penna F. Are there any benefits of exercise training in cancer cachexia? J Cachexia Sarcopenia Muscle 2012;3:73-6.
44. Penna F, Pin F, Ballarò R, Baccino FM, Costelli P. Novel investigational drugs mimicking exercise for the treatment of cachexia. Expert Opin Investig Drugs 2016;25:63-72.
45. Vainshtein A, Tryon LD, Pauly M, Hood DA. Role of PGC-1α during acute exercise-induced autophagy and mitophagy in skeletal muscle. Am J Physiol - Cell Physiol 2015;308:C710-9.
46. Brandt N, Dethlefsen MM, Bangsbo J, Pilegaard H. PGC-1 α and exercise intensity dependent adaptations in mouse skeletal muscle. PLoS One 2017;12:e0185993.
47. Garcia S, Nissanka N, Mareco EA, Rossi S, Peralta S, et al. Overexpression of PGC-1 a in aging muscle enhances a subset of young-like molecular patterns. Aging Cell 2018;17.
48. Lin J, Wu H, Tarr P, Zhang C, Wu Z, et al. Transcriptional co-activator PGC-1 a drives the formation of slow-twitch muscle fibre. Nature 2002;418:797-801.
49. Dinulovic I, Furrer R, Beer M, Ferry A, Cardel B, et al. Muscle PGC-1 α modulates satellite cell number and proliferation by remodeling the stem cell niche. Skelet Muscle 2016;6:39.
50. Cannavino J, Brocca L, Sandri M, Bottinelli R, Pellegrino MA. PGC1- α over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J Physiol 2014;20:4575-89.
52. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A 2006;103:16260-5.
53. Gill JF, Santos G, Schnyder S, Handschin C. PGC-1α affects aging-related changes in muscle and motor function by modulating specific exercise-mediated changes in old mice. Aging Cell 2018;17:1-13.
54. van der Ende M, Grefte S, Plas R, Meijerink J, Witkamp RF, et al. Mitochondrial dynamics in cancer-induced cachexia. Biochim Biophys Acta - Rev Cancer 2018;1870:137-50.
55. Wang X, Pickrell AM, Zimmers TA, Moraes CT. Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia. PLoS One 2012;7:2-7.
56. Vaughan RA, Mermier CM, Bisoffi M, Trujillo KA, Conn CA. Dietary stimulators of the PGC-1 superfamily and mitochondrial biosynthesis in skeletal muscle. A mini-review. J Physiol Biochem 2014;70:271-84.
57. Wang L, Di L, Noguchi CT. Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system. Int J Biol Sci 2014;10:921-39.
58. Cui L, Guo J, Zhang Q, Yin J, Li J, et al. Erythropoietin activates SIRT1 to protect human cardiomyocytes against doxorubicin-induced mitochondrial dysfunction and toxicity. Toxicol Lett 2017;275:28-38.
59. Wang L, Jia Y, Rogers H, Suzuki N, Gassmann M, et al. Erythropoietin contributes to slow oxidative muscle fiber specification via PGC-1α and AMPK activation. Int J Biochem Cell Biol 2014;45:1155-64.
60. Plenge U, Belhage B, Guadalupe-Grau A, Andersen PR, Lundby C, et al. Erythropoietin treatment enhances muscle mitochondria capacity in humans. Front Physiol 2012;3:1-5.
61. Lopaschuk DG, Barr R, Panakkezhum DT, Dyck RJ. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 2003;93:e33-7.
62. Dyck JRB. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 2004;94:e78-84.
63. Guarini G, Huqi A, Morrone D, Francesca P, Capozza G, et al. Pharmacotherapy Trimetazidine and Other Metabolic Modifiers. Eur Cardiol 2018;13:104-11.
64. Vitale C, Marazzi G, Pelliccia F, Volterrani M, Cerquetani E, et al. Trimetazidine improves exercise performance in patients with peripheral arterial disease. Pharmacol Res 2011;63:278-83.
65. Kuzmicic J, Parra V, Verdejo HE, López-Crisosto C, Chiong M, et al. Trimetazidine prevents palmitate-induced mitochondrial fission and dysfunction in cultured cardiomyocytes. Biochem Pharmacol 2014;91:323-36.
66. Ferraro E, Giammarioli AM, Caldarola S, Lista P, Feraco A, et al. The metabolic modulator trimetazidine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes. FEBS J 2013;280:5094-108.
67. Ferraro E, Pin F, Gorini S, Pontecorvo L, Ferri A, et al. Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine. J Cachexia Sarcopenia Muscle 2016;7:449-57.
68. Molinari F, Pin F, Gorini S, Chiandotto S, Pontecorvo L, et al. The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice. J Cachexia Sarcopenia Muscle 2017;8:954-73.
69. Blaauw B, Schiaffino S, Reggiani C. Mechanisms modulating skeletal muscle phenotype. Compr Physiol 2013;3:1645-87.
70. Bazgir B, Fathi R, Valojerdi MR, Mozdziak P, Asgari A. Satellite cells contribution to exercise mediated muscle hypertrophy and repair. Cell J 2016;18:473-84.
71. Gatta L, Vitiello L, Gorini S, Chiandotto S, Costelli P, et al. Modulating the metabolism by trimetazidine enhances myoblast differentiation and promotes myogenesis in cachectic tumor-bearing c26 mice. Oncotarget 2017;8:113938-56.
72. He WA, Berardi E, Cardillo VM, Acharyya S, Aulino P, et al. NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest 2013;123:4821-35.
